Alveolar-capillary endocytosis and trafficking in acute lung injury and acute respiratory distress syndrome

Front Immunol. 2024 Mar 12:15:1360370. doi: 10.3389/fimmu.2024.1360370. eCollection 2024.

Abstract

Acute respiratory distress syndrome (ARDS) is associated with high morbidity and mortality but lacks specific therapeutic options. Diverse endocytic processes play a key role in all phases of acute lung injury (ALI), including the initial insult, development of respiratory failure due to alveolar flooding, as a consequence of altered alveolar-capillary barrier function, as well as in the resolution or deleterious remodeling after injury. In particular, clathrin-, caveolae-, endophilin- and glycosylphosphatidyl inositol-anchored protein-mediated endocytosis, as well as, macropinocytosis and phagocytosis have been implicated in the setting of acute lung damage. This manuscript reviews our current understanding of these endocytic pathways and subsequent intracellular trafficking in various phases of ALI, and also aims to identify potential therapeutic targets for patients with ARDS.

Keywords: acute respiratory distress syndrome; caveolae; clathrin-mediated endocytosis; endophilin; glycosylphosphatidyl inositol-anchored protein enriched early endosomal compartment pathway; macropinocytosis; phagocytosis; trafficking.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury* / therapy
  • Endocytosis
  • Humans
  • Phagocytosis
  • Pinocytosis
  • Respiratory Distress Syndrome* / therapy

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported in part by grants from the German Federal Ministry of Education and Research (German Center for Lung Research [DZL/ALI 1.5, 3.3 and 3.4]), the von Behring Röntgen Foundation (Project 66-LV07), the German Research Foundation (DFG/KFO309, project ID: 284237345; P5; The Cardio-Pulmonary Institute (EXC 2026, project ID: 390649896) (to IV) and an MD/PhD start-up grant (DFG/KFO309, MD/PhD) (to VK).